VENTYX BIOSCIENCES INC. - COMMON STOCK

Ventyx Biosciences Announces First Patient Dosed in a Phase 2 Clinical Trial of VTX002 for the Treatment of Moderate-to-Severe Ulcerative Colitis

06 ديسمبر 2021 08:00:01 بحسب Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

19 نوفمبر 2021 08:00:00 بحسب Nasdaq GlobeNewswire

Ventyx Biosciences Reports Third Quarter Financial Results and Provides Business Update

17 نوفمبر 2021 16:11:04 بحسب Nasdaq GlobeNewswire

Ventyx Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

25 أكتوبر 2021 16:58:33 بحسب Nasdaq GlobeNewswire

Ventyx Biosciences Announces Pricing of Upsized Initial Public Offering

20 أكتوبر 2021 20:38:40 بحسب Nasdaq GlobeNewswire